eilon kirson md phd executive profile  biography  bloomberg july    am et healthcare equipment and supplies company overview of novocure limited snapshotpeople  overviewboard memberscommittees executive profile eilon kirson md phdchief science officer and head of research  development novocure limitedagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriesas of fiscal year  background dr eilon kirson md phd has been the chief science officer and head of research  development at novocure limited since  and served as its chief medical officer from  to  dr kirson joined novocure in  and has global responsibility for novocure’s clinical and product development programs as well as its regulatory strategy he served as a vice president of r  d at novocure limited he leads novocures research and development activities in this  role he has had responsibility at novocures preclinical research clinical planning and interactions at the fda before novocure he served as the head of electrophysiology at carmel biosensensors dr kirson received his bmedsc md and phd in physiologybiophysics from the hebrew university and underwent his residency in neurology at sheba medical center tel hashomer hospital israelread full background corporate headquarters le masurier housesaint helier jersey je yechannel islandsphone    fax  board members memberships there is no board members memberships data available education unknownother education hebrew university of jerusalemphd hebrew university of jerusalemmd hebrew university of jerusalem other affiliations hebrew university of jerusalemnovocure inc annual compensation salarytotal annual compensation stocks options all other compensationexercisable optionsunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact novocure limited please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close eilon kirson md phd  novocure search contact us careers news and media eilon kirson md phd chief science officer and head of research and development dr eilon kirson joined novocure in  and served as chief medical officer until  when he was promoted to chief science officer and head of research and development dr kirson has global responsibility for novocure’s preclinical and clinical and product development programs as well as the company’s regulatory strategy throughout his tenure at novocure dr kirson has led the development of ttfields therapy from preclinical testing to large multicenter phase iii studies and through multiple regulatory approvals dr kirson previously served as head of electrophysiology at carmel biosensensors dr kirson received his bmedsc md and phd in biophysics from the hebrew university and underwent his residency in neurology at sheba medical center tel hashomer hospital israel all leadership about us corporate timeline professor yoram palti founded novocure in  we have since accomplished many significant milestones leadership meet our leaders who have extensive experience across oncology biotechnology and medical device industries corporate presentation we pioneer a profoundly different approach to treating cancer called tumor treating fields our therapy mechanism of action our proprietary technology – tumor treating fields – disrupts cell division through physical interactions with key molecules during mitosis delivery method we deliver tumor treating fields through a noninvasive portable medical device that targets solid tumors with no known systemic toxicities treating cancer with electric fields treatment with tumor treating fields has become a fourth modality in cancer care our pipeline clinical trials our mechanism of action is broadly applicable across a variety of solid tumors publications we have more than  years of research and multiple peerreviewed publications with preclinical data in  cancer types and clinical data in eight cancer types novocuretrialcom the science of tumor treating fields extends beyond glioblastoma we are conducting clinical trials in brain metastases nonsmall cell lung cancer pancreatic cancer ovarian cancer and mesothelioma patientforward news and media media gallery featured stories investor relations press releases corporate presentation events annual reports sec filings stock information corporate governance faq email alerts careers working with us our locations current job listings eilon kirson  novocure ltd  zoominfocom nvcr eilon d kirson insider trades for novocure ltd bulletin mcdonalds shares gain as earnings report includes strong samestore sales rise » investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close novocure ltd nasdaq nvcr go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus novocure ltd after hours  quotes are delayed by  min jul    pm nvcr quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual eilon d kirson dr eilon d kirson md phd is chief science officer headresearch  development at novocure ltd dr kirson was previously employed as a principal by sheba medical center he received his undergraduate degree from the hebrew university of jerusalem and a doctorate degree from the hebrew university of jerusalem transactions date shares transaction value          award at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr asaf danziger chief executive officer  director dr yoram palti director  chief technology officer mr martin j madden director ms ashley cordova headinvestor relations  media mr charles g phillips independent director mr louis j lavigne independent director mr william anthony vernon independent director mr william burkoth independent director mr gert lennart perlhagen independent class ii director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest acaterpillar beats earnings views lifts outlook atintri started at overweight with  stock price target at keybanc capital aneuralstem stock halted on news of midstage clinical trial miss atintri started at outperform with  stock price target at raymond james awebmd downgraded to market perform from outperform at raymond james aspectranetics downgraded to market perform from outperform at raymond james asierra bancorp upgraded to outperform from market perform at raymond james aalphabet stock price target raised to  from  at raymond james amcdonalds expects to net restaurant additions of  in  amcdonalds expects to have  experience of the future restaurants in us by end of  abreakingcaterpillar mcdonalds stocks set to add about  points to dow industrials aseagate technologys stock plunges after profit and sales miss ceo change aneuralstem stock halted on news of midstage clinical trial miss afreeportmcmoran shares gain  after company swings to a profit in q ainvesting lessons from edward thorp quant pioneer and card counter awe’re reaching the dangerous ninth inning for commercial real estate aneuralstem shares halted premarket for news pending awhat the solar eclipse on aug  will mean for stocks amcdonalds shares rise after earnings revenue beat estimates aseagate technologys stock plunges  premarket after q results ceo transition loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  form  novocure ltd for jun  filed by kirson eilon d research stocks news story skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  news  events  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print format change text size default text sizea larger text sizea largest text sizea form  novocure ltd for jun  filed by kirson eilon d by k wizard—  pm et  httparchivefastedgarcomaozsuczhiczhpzr filed on june   more nvcr news novocure announces change to presentation time at the jmp securities  life sciences conference business wire   pm et  first patient enrolled in rtog trial of optune® together with bevacizumab for patients with bevacizumabrefractory recurrent glioblastoma business wire   am et  health care service corporation issues positive coverage decision for optune business wire   am et  copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top vly log in for events bac tgna wafd hafc mcf log in for events ati rpd hil cdxs find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  am et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  nvcr stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsnvcr novocure ltd    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all briefnovocure to initiate earlystage trial testing its glioblastoma combo therapy reuters –  am et  novocure ltd nvcr  novocure™ announces a phase b clinical trial to evaluate the safety of marizomib and temozolomide in combination with optune® as adjuvant therapy in patients with glioblastoma novocure™ announces a phase b clinical trial to evaluate the safety of marizomib and temozolomide in combination with optune® as adjuvant therapy in patients with glioblastoma business wire –  am et  this trial is the first to study optune in combination with an investigational drug novocure nvcr announced today a new arm for a phase b study to evaluate the safety of marizomib and temozolomide in combination with optune novocure’s tumor treating fields delivery system as adjuvant treatment for patients with newly diagnosed glioblastoma following radiation therapy with concurrent temozolomide many treatment options most experimental available to john mccain reuters –  am et  there is at least one approved device and scores of experimental treatments being tested that could improve the odds of longerterm survival for patients with the type of extremely aggressive brain cancer afflicting us senator john mccain many treatment options most experimental available to john mccain reuters –  pm et  there is at least one approved device and scores of experimental treatments being tested that could improve the odds of longerterm survival for patients with the type of extremely aggressive brain cancer afflicting us senator john mccain todays research report coverage on medical equipment stocks  novocure corindus vascular robotics inspiremd and nxstage medical pr newswire –  am et  new york july   if you want a stock review on nvcr cvrs nspr or nxtm then come over to httpdailystocktrackercomregister and sign up for your free customized report today httpdailystocktrackercomregister novocure  last friday saint helier the channel islandsbased novocure ltds nvcr stock dropped  to close the day at  a total volume of  shares was traded novocure’s optune® now available at more than  cancer treatment centers in the us business wire –  am et  company broadens geographic reach of optune in community setting making therapy more accessible to patients internationally gbm patients can access optune at an additional  medical institutions novocure™ announced today that physicians at more than  cancer treatment centers in the us have been certified to prescribe optune to newly diagnosed and recurrent glioblastoma patients data on delivery of tumor treating fields to be presented at the th annual international conference of the ieee engineering in medicine and biology society business wire –  am et  three oral presentations underscore novocures commitment to further understanding the physical application of tumor treating fields to enhance efficacy novocure nvcr announced today that three oral presentations on tumor treating fields will be given at the th annual international conference of the ieee engineering in medicine and biology society on july  through july  in jeju island korea novocure to report second quarter  financial results business wire –  am et  novocure nvcr announced today that it will report financial results for the second quarter  on thursday july   before the usbased financial markets open analysts and investors can participate in the conference call by dialing  for domestic callers and  for international callers using the conference id  novocure to present three abstracts on tumor treating fields and pancreatic cancer at the european society for medical oncology th world congress on gastrointestinal cancer business wire –  am et  a phase  pivotal trial  panova  will test the efficacy of ttfields with gemcitabine and nabpaclitaxel as a frontline treatment of locally advanced pancreatic cancer novocure nvcr announced today that the company will present three abstracts studying tumor treating fields in pancreatic cancer at the european society for medical oncology th world congress on gastrointestinal cancer on june  novocure announces change to presentation time at the jmp securities  life sciences conference business wire –  pm et  novocure nvcr announced today that the time of its presentation at the jmp securities  life sciences conference has changed a live audio webcast of the presentation can be accessed from the investor relations page of novocures website wwwnovocurecominvestorrelations and will be available for replay for at least  days following the call first patient enrolled in rtog trial of optune® together with bevacizumab for patients with bevacizumabrefractory recurrent glioblastoma business wire –  am et  the rtog  phase  pilot trial is the first consortium study to test treatment with optune novocure™ announced today that the first patient has been enrolled in the rtog foundation’s phase  pilot trial testing optune together with bevacizumab for patients with bevacizumabrefractory recurrent glioblastoma health care service corporation issues positive coverage decision for optune business wire –  am et  more than  million americans will have coverage of optune as a treatment for newly diagnosed andor recurrent glioblastoma novocure nvcr announced today that health care service corporation will cover optune for members who have newly diagnosed glioblastoma effective june   novocure to present at the jmp securities  life sciences conference business wire –  am et  novocure nvcr announced today that it will participate in the jmp securities  life sciences conference on june   in new york dr kirsons presentation will begin at  pm edt and will be followed by a qa session research reports initiation on medical equipment stocks  masimo novocure nxstage medical and varex imaging pr newswire –  am et  new york may   on friday may   us markets saw broad based gains with all nine sectors finishing the trading sessions in green httpstockcallerscomregistration masimo masi   irvine california headquartered masimo corps masi stock finished last fridays session  higher at  a total volume of  shares was traded httpstockcallerscomregistrationsymbolmasi novocure™ receives humanitarian use device designation for treatment of pleural mesothelioma business wire –  am et  novocure nvcr announced today that united states food and drug administration has designated its tumor treating fields delivery system as a humanitarian use device for the treatment of pleural mesothelioma hud designation covers devices that treat rare orphan diseases or conditions martin j madden joins novocure board of directors business wire –  am et  novocure nvcr today announced that martin j madden a longtime leader in the medical device industry was elected to its boards of directors during novocures  annual general meeting of shareholders combination of optune™ with standard of care chemotherapy temozolomide delayed decline in several healthrelated quality of life scales compared to temozolomide alone for newly diagnosed glioblastoma patients business wire –  am et  addition of optune to temozolomide did not negatively impact quality of life for newly diagnosed glioblastoma patients except for causing itchy skin novocure™ announced today results from healthrelated quality of life analyses from its phase  pivotal ef trial adding optune to standard temozolomide chemotherapy for the treatment of newly diagnosed glioblastoma novocure™ announces opening of two pilot trials to evaluate the use of ttfields for pediatric gliomas business wire –  am et  trials sponsored by the pediatric brain tumor consortium and hackensack university medical center now open and recruiting novocure nvcr announced today two pilot trials are open and actively recruiting pediatric patients with high grade gliomas to evaluate the safety and feasibility of tumor treating fields in this population novocure to present at three upcoming investor conferences in may business wire –  am et  novocure nvcr announced today that it will participate in three upcoming investor conferences in may william doyle novocures executive chairman will participate in a fireside chat at the deutsche bank nd annual health care conference on may   in boston mr doyle will also present at the ubs  global healthcare conference on may   in new york novocure™ announces data presentations at the world federation of neurooncology societies th quadrennial meeting business wire –  am et  analysis showing patients treated with optune® in combination with temozolomide for newly diagnosed glioblastoma reported an unprecedented fiveyear survival advantage to be shared during an oral presentation novocure nvcr announced today that ten data presentations investigating the use of tumor treating fields for the treatment of glioblastoma will be presented at this year’s world federation o page page   next  todays and upcoming events jul  nvcr to announce q earnings before market confirmed jul  nvcr earnings conference call at  am listen past events last  days no events in the past  days data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe eilon kirson  novocure ltd  zoominfocom   form  novocure ltd for jul  filed by kirson eilon d research stocks news story skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  news  events  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print format change text size default text sizea larger text sizea largest text sizea form  novocure ltd for jul  filed by kirson eilon d by k wizard—  pm et  httparchivefastedgarcomaozsuczlbiwzhrzrz filed on july   more nvcr news novocure to report second quarter  financial results business wire   am et  novocure to present three abstracts on tumor treating fields and pancreatic cancer at the european society for medical oncology th world congress on gastrointestinal cancer business wire   am et  novocure announces change to presentation time at the jmp securities  life sciences conference business wire   pm et  copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top vly log in for events bac tgna wafd hafc mcf log in for events ati rpd hil cdxs find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  am et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  nvcr stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsnvcr novocure ltd    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all briefnovocure to initiate earlystage trial testing its glioblastoma combo therapy reuters –  am et  novocure ltd nvcr  novocure™ announces a phase b clinical trial to evaluate the safety of marizomib and temozolomide in combination with optune® as adjuvant therapy in patients with glioblastoma novocure™ announces a phase b clinical trial to evaluate the safety of marizomib and temozolomide in combination with optune® as adjuvant therapy in patients with glioblastoma business wire –  am et  this trial is the first to study optune in combination with an investigational drug novocure nvcr announced today a new arm for a phase b study to evaluate the safety of marizomib and temozolomide in combination with optune novocure’s tumor treating fields delivery system as adjuvant treatment for patients with newly diagnosed glioblastoma following radiation therapy with concurrent temozolomide many treatment options most experimental available to john mccain reuters –  am et  there is at least one approved device and scores of experimental treatments being tested that could improve the odds of longerterm survival for patients with the type of extremely aggressive brain cancer afflicting us senator john mccain many treatment options most experimental available to john mccain reuters –  pm et  there is at least one approved device and scores of experimental treatments being tested that could improve the odds of longerterm survival for patients with the type of extremely aggressive brain cancer afflicting us senator john mccain todays research report coverage on medical equipment stocks  novocure corindus vascular robotics inspiremd and nxstage medical pr newswire –  am et  new york july   if you want a stock review on nvcr cvrs nspr or nxtm then come over to httpdailystocktrackercomregister and sign up for your free customized report today httpdailystocktrackercomregister novocure  last friday saint helier the channel islandsbased novocure ltds nvcr stock dropped  to close the day at  a total volume of  shares was traded novocure’s optune® now available at more than  cancer treatment centers in the us business wire –  am et  company broadens geographic reach of optune in community setting making therapy more accessible to patients internationally gbm patients can access optune at an additional  medical institutions novocure™ announced today that physicians at more than  cancer treatment centers in the us have been certified to prescribe optune to newly diagnosed and recurrent glioblastoma patients data on delivery of tumor treating fields to be presented at the th annual international conference of the ieee engineering in medicine and biology society business wire –  am et  three oral presentations underscore novocures commitment to further understanding the physical application of tumor treating fields to enhance efficacy novocure nvcr announced today that three oral presentations on tumor treating fields will be given at the th annual international conference of the ieee engineering in medicine and biology society on july  through july  in jeju island korea novocure to report second quarter  financial results business wire –  am et  novocure nvcr announced today that it will report financial results for the second quarter  on thursday july   before the usbased financial markets open analysts and investors can participate in the conference call by dialing  for domestic callers and  for international callers using the conference id  novocure to present three abstracts on tumor treating fields and pancreatic cancer at the european society for medical oncology th world congress on gastrointestinal cancer business wire –  am et  a phase  pivotal trial  panova  will test the efficacy of ttfields with gemcitabine and nabpaclitaxel as a frontline treatment of locally advanced pancreatic cancer novocure nvcr announced today that the company will present three abstracts studying tumor treating fields in pancreatic cancer at the european society for medical oncology th world congress on gastrointestinal cancer on june  novocure announces change to presentation time at the jmp securities  life sciences conference business wire –  pm et  novocure nvcr announced today that the time of its presentation at the jmp securities  life sciences conference has changed a live audio webcast of the presentation can be accessed from the investor relations page of novocures website wwwnovocurecominvestorrelations and will be available for replay for at least  days following the call first patient enrolled in rtog trial of optune® together with bevacizumab for patients with bevacizumabrefractory recurrent glioblastoma business wire –  am et  the rtog  phase  pilot trial is the first consortium study to test treatment with optune novocure™ announced today that the first patient has been enrolled in the rtog foundation’s phase  pilot trial testing optune together with bevacizumab for patients with bevacizumabrefractory recurrent glioblastoma health care service corporation issues positive coverage decision for optune business wire –  am et  more than  million americans will have coverage of optune as a treatment for newly diagnosed andor recurrent glioblastoma novocure nvcr announced today that health care service corporation will cover optune for members who have newly diagnosed glioblastoma effective june   novocure to present at the jmp securities  life sciences conference business wire –  am et  novocure nvcr announced today that it will participate in the jmp securities  life sciences conference on june   in new york dr kirsons presentation will begin at  pm edt and will be followed by a qa session research reports initiation on medical equipment stocks  masimo novocure nxstage medical and varex imaging pr newswire –  am et  new york may   on friday may   us markets saw broad based gains with all nine sectors finishing the trading sessions in green httpstockcallerscomregistration masimo masi   irvine california headquartered masimo corps masi stock finished last fridays session  higher at  a total volume of  shares was traded httpstockcallerscomregistrationsymbolmasi novocure™ receives humanitarian use device designation for treatment of pleural mesothelioma business wire –  am et  novocure nvcr announced today that united states food and drug administration has designated its tumor treating fields delivery system as a humanitarian use device for the treatment of pleural mesothelioma hud designation covers devices that treat rare orphan diseases or conditions martin j madden joins novocure board of directors business wire –  am et  novocure nvcr today announced that martin j madden a longtime leader in the medical device industry was elected to its boards of directors during novocures  annual general meeting of shareholders combination of optune™ with standard of care chemotherapy temozolomide delayed decline in several healthrelated quality of life scales compared to temozolomide alone for newly diagnosed glioblastoma patients business wire –  am et  addition of optune to temozolomide did not negatively impact quality of life for newly diagnosed glioblastoma patients except for causing itchy skin novocure™ announced today results from healthrelated quality of life analyses from its phase  pivotal ef trial adding optune to standard temozolomide chemotherapy for the treatment of newly diagnosed glioblastoma novocure™ announces opening of two pilot trials to evaluate the use of ttfields for pediatric gliomas business wire –  am et  trials sponsored by the pediatric brain tumor consortium and hackensack university medical center now open and recruiting novocure nvcr announced today two pilot trials are open and actively recruiting pediatric patients with high grade gliomas to evaluate the safety and feasibility of tumor treating fields in this population novocure to present at three upcoming investor conferences in may business wire –  am et  novocure nvcr announced today that it will participate in three upcoming investor conferences in may william doyle novocures executive chairman will participate in a fireside chat at the deutsche bank nd annual health care conference on may   in boston mr doyle will also present at the ubs  global healthcare conference on may   in new york novocure™ announces data presentations at the world federation of neurooncology societies th quadrennial meeting business wire –  am et  analysis showing patients treated with optune® in combination with temozolomide for newly diagnosed glioblastoma reported an unprecedented fiveyear survival advantage to be shared during an oral presentation novocure nvcr announced today that ten data presentations investigating the use of tumor treating fields for the treatment of glioblastoma will be presented at this year’s world federation o page page   next  todays and upcoming events jul  nvcr to announce q earnings before market confirmed jul  nvcr earnings conference call at  am listen past events last  days no events in the past  days data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe eilon kirson chief medical officer novocure timesjavascript is disabled market profiles login sign up login sign up   edit person eilon kirson chief medical officer at novocure location united state add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop eilon kirson chief medical officer at novocure location united state add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop dr kirson joined novocure in  and served as chief medical officer until  when he was promoted to chief science officer and head of research and development dr kirson has global responsibility for novocure’s preclinical and clinical and product development programs as well as the company’s regulatory strategy in his tenure at novocure dr kirson has led the development of ttfields therapy from preclinical testing to large multicenter phase iii studies and through multiple regulatory approvals dr kirson previously served as head of electrophysiology at carmel biosensensors dr kirson received his bmedsc md and phd in biophysics from the hebrew university and underwent his residency in neurology at sheba medical center tel hashomer hospital israel  companies in career na related markets  colleagues na related investments alias na industry pharmaceuticals tags na topics of influence na na careers achievements investments related people edit view all eilon kirsoncareer  novocure chief medical officer competencies edit view all eilon kirsoneducation  hebrew university medicine hebrew university biophysics hebrew university edit eilon kirsonachievements and recognitions add milestone no milestones has been recorded for eilon kirson edit eilon kirsonlinks add link no links has been recorded for eilon kirson eilon kirsoninvestmentsacquisitions no investments has been recorded for eilon kirson eilon kirsoninvestments representing others no investment reps has been recorded for eilon kirson eilon kirsonrelated people colleagues at novocure todd longsworth general counsel may wilco groenhuysen chief financial officer jan peter melnyk chief commercial officer sep mike ambrogi chief operating officer  view all peers  jonathan fox chief medical officer of myokardia henry dephillips chief medical officer of teladoc richard messmann chief medical officer of pronai therapeutics anthony boral chief medical officer of blueprint medicines william prince chief medical officer of nabriva therapeutics leni ramos chief medical officer of global blood therapeutics view all eilon kirsonrecommended market profiles healthcare ipo companies  or more employees  companies microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft eilon kirson  netfind content results aol search skip over navigation search the web web web content results from the wowcom content network alternating electric field therapy  wowcom wwwwowcomwikitumortreatingfields alternating electric field therapy  ttf was initially described in  as the use of insulated electrodes to  kirson eilon d dbaly v tovarys f  search the web  aol inc all rights reservedprivacy   terms of use   preferences   contact us   powered by bing™ wowcom  part of the aol search network